DENVER, CO -- May 15, 2017 -- InvestorsHub NewsWire --
AmeriCann, Inc. (OTCQX: ACAN), an Agricultural-Technology company that
is developing the next generation of sustainable, state-of-the-art,
energy efficient medical cannabis cultivation properties, is
continuing to receive interest from an increasing number of
national financial publications.
The expanded media coverage includes recent mentions in Forbes,
Barrons, CNN Money, MarketWatch, The Wall Street Journal and
others. Additionally, Morningstar Research issued a report on May 4
rating ACAN as Undervalued with a Fair Value of $6.27 per
share.
The Companys flagship Massachusetts Medical Cannabis Center
(MMCC) project is 47 miles from Boston in the midst of the rapidly
growing Massachusetts medical cannabis market. The MMCC project is
approved for 1 million square feet, which will be developed in
phases and is expected to be one of the most technologically
advanced cultivation facilities in the nation. The company is
planning to replicate the MMCC technology in additional states.
Media links:
https://www.forbes.com/sites/debraborchardt/2017/05/08/the-marijuana-industry-is-getting-super-sized/#6f1d588e126e
http://www.barrons.com/articles/PR-CO-20170505-914172
http://money.cnn.com/news/newsfeeds/articles/prnewswire/enUK201705050762.htm
http://www.marketwatch.com/story/the-creation-of-jobs-in-the-legal-cannabis-market-2017-05-05
https://www.wsj.com/articles/PR-CO-20170505-914172
AmeriCann was also recently added to two Marijuana stock
indices:
About AmeriCann
AmeriCann (OTCQX: ACAN) is a publicly traded Agricultural
Technology (Ag-Tech) company that is developing a new generation of
sustainable, state-of-the-art medical cannabis cultivation and
processing properties. The Company has over 1,000,000 square feet
of facilities in the planning and design stages of development.
AmeriCann, Inc. is a Certified B
Corp, an acknowledgment of the companys commitment to social
and environmental ethics, transparency and accountability. AmeriCann became the first public
cannabis company to earn this respected accreditation. More
information about the Company is available at: www.americann.co or follow AmeriCann on Twitter @ACANinfo
About Solanna
AmeriCann, Inc. has developed and owns Solanna, a new
comprehensive line of nutraceutical-grade cannabis infused
products. The company has created the brand, packaging concepts and
invested significantly in Standard Operating Procedures and Good
Manufacturing Practices to ensure safety, consistency and efficacy
across the product offering.
The intellectual property for Solanna will be licensed by
AmeriCann to regulated cannabis businesses and will initially focus
on providing healthier alternatives to smoking that include:
- Capsules
- Topical lotions and balms
- Sublingual tinctures
- Oral dissolving film
- Trans-dermal applications
The Company plans to expand the product line to include edible
products, health drinks, and branded concentrates. The
products are designed to allow consumers to manage dosage through
micro-dosing and to improve efficacy by incorporating blends of
other plants, essential oils and other supplements that enhance and
compliment the benefits of cannabis.
The Solanna line of products will be offered exclusively through
AmeriCanns Preferred Partners.
About Massachusetts Medical Cannabis Center (MMCC)
The Massachusetts Medical Cannabis Center is approved for
nearly 1,000,000 square feet of medical cannabis
cultivation and processing in Freetown, Massachusetts. The
state-of-the-art, sustainable, greenhouse project will consist of
multiple planned phases for tenants in the Massachusetts medical
marijuana market.
AmeriCanns Cannopy System uniquely combines expertise from
traditional horticulture, lean manufacturing, regulatory compliance
and cannabis cultivation to create superior facilities and
procedures.
The first phase of the project consists of 160,000 sq. ft. of
cultivation and processing infrastructure. AmeriCann can expand the
first phase to approximately 600,000 sq. ft., based on patient
demand.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended (the Exchange Act) (which Sections were adopted as part of
the Private Securities Litigation Reform Act of 1995). Statements
preceded by, followed by or that otherwise include the words
believe, anticipate, estimate, expect, intend, plan, project,
prospects, outlook, and similar words or expressions, or future or
conditional verbs such as will, should, would, may, and could are
generally forward-looking in nature and not historical facts. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the Company's
actual results, performance or achievements to be materially
different from any anticipated results, performance or
achievements. The Company disclaims any intention to, and
undertakes no obligation to, revise any forward-looking statements,
whether as a result of new information, a future event, or
otherwise. For additional uncertainties that could impact the
Company's forward-looking statements, please see the Companys
Annual Report on Form 10-K for the year ended September 30, 2016,
which the Company has filed with the SEC and which may be viewed at
http://www.sec.gov.
Contact Information:
Corporate:
AmeriCann, Inc.
3200 Brighton Blvd. Unit 114
Denver, CO 80216
(303) 862-9000
info@americann.co
www.americann.co
@ACANinfo on Twitter
Investors:
Hayden IR
hart@haydenir.com
(917) 658-7878
AmeriCann Press Release re Publications 5-11-17